ClinicalTrials.gg
CompletedNCT03520036Updated Dec 31, 2025Results posted

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

A Phase 2 interventional study of MT-7117 low dose and MT-7117 high dose in Erythropoietic Protoporphyria (EPP), sponsored by Tanabe Pharma America, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Enrollment
5th of 13
102 · median 77
Started
2018
the only one that year
Phase 2
5 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
2 of 18
Tanabe Pharma America, Inc.

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2018, is one of 5 in phase 2, and was the 9th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight exposure duration without symptoms and tolerance in subjects with EPP.

Read the detailed description

This is a Phase 2, randomized, double-blind, placebo controlled study to assess the efficacy, tolerability, and safety of MT-7117 in subjects with EPP. The study consists of a 2 week screening period, a 16 week double-blind treatment period, and a 6 week follow-up period at Week 22. The total participation period is approximately 24 weeks.

03

Conditions studied

  • Erythropoietic Protoporphyria (EPP)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Additional screening criteria check may apply for qualification.

Inclusion criteria

Inclusion Criteria:

  • 1. Subjects provided written to participate.
  • 2. Male and female subjects with a confirmed diagnosis of EPP based on medical history, aged 18 years to 75 years, inclusive, at Screening.
  • 3. Subjects are willing and able to travel to the study sites for all scheduled visits.
  • 4. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements (including travel).

Exclusion criteria

Exclusion Criteria:

  • 1. History or presence of photodermatoses other than EPP.
  • 2. Subjects who are unwilling or unable to go outside during daylight hours (e.g., between 1 hour post sunrise and 1 hour pre-sunset) during the study.
  • 3. Presence of hepatobiliary disease based on LFT values at Screening.
  • 4. Subjects with , ALT, ALP ≥3.0 × (ULN) or total >1.5 × ULN at Screening.
  • 5. Subjects with or having a history (in the last 2 years) of excessive alcohol intake in the opinion of the Investigator.
  • 6. History or presence of melanoma and/or atypical nevus at Screening.
  • 7. History of familial melanoma (defined as having 2 or more first-degree relatives, such as parents, sibling and/or child).
  • 8. History or presence of pre-malignant skin lesion squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions.
  • 9. History or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subjects.
  • 10. Presence of clinically significant acute or chronic renal disease based upon the subject's medical records including hemodialysis; and a serum creatinine level of greater than 1.2 mg/dL or a (GFR) \<60 ml/min.
  • 11. Presence of any clinically significant disease or laboratory abnormality which, in the opinion of the Investigator, can interfere with the study objectives and/or safety of the subjects.
  • 12. Pregnancy or lactation.
  • 13. Females of child bearing potential and male subjects with partners of unwilling to use adequate measures as described in the protocol.
  • 14. Treatment with phototherapy within 3 months before Randomization (Visit 2).
  • 15. Treatment with afamelanotide within 3 months before Randomization (Visit 2).
  • 16. Treatment with cimetidine within 4 weeks before Randomization (Visit 2).
  • 17. Treatment with antioxidant agents at doses which, in the opinion of the Investigator, may affect study endpoints (including but not limited to beta-carotene, cysteine, pyridoxine) within 4 weeks before Randomization (Visit 2).
  • 18. Chronic treatment with prescription-based analgesic agents including but not limited to opioids and opioid derivatives such as morphine, hydrocodone, oxycodone or their combination with other analgesics or non-steroidal anti-inflammatory drug (NSAID, as Percocet and Vicodin-like prescription drugs) within 4 weeks before Randomization (Visit 2).
  • 19. Treatment with any drugs or supplements which, in the opinion of the Investigator, can interfere with the objectives of the study or safety of the subjects.
  • 20. Previous exposure to MT 7117.
  • 21. Previous treatment with any agent within 12 weeks before Screening OR 5 half-lives of the investigational product (whichever is longer).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    MT-7117 low dose

    Drug: MT-7117 low dose

  • Experimental
    MT-7117 high dose

    Drug: MT-7117 high dose

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16.

    Duration in minutes, of sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset. The average Duration in minutes, of sunlight exposure before the first prodromal symptom between 1 hour post sunrise and 1 hour pre-sunset. The average duration means that average of daily durations in 14-day windows before Day 1 (or week 16 Day) applied.

    Time frame: Baseline (Week 0) and Week 16

  2. Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16

    Change from baseline to week 16 in Average Daily Duration (Minutes) of Sunlight Exposure sums any sunlight exposure time excluding any overlapped time with prodromal symptoms, including if the patients go out multiple times on the same day after the prodromal symptom had previously ended.

    Time frame: Baseline (Week 0), and Week 16

  3. Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16

    Change from baseline to week 16 in Average Daily Mean Duration (Minutes) of Sunlight Exposure without prodromal symptoms divided by the number of sunlight exposures periods applicable that day.

    Time frame: Baseline (Week 0), and Week 16

Secondary outcomes

  1. Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period

    Time frame: Week 16

  2. Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale

    The Intensity of Prodromal Symptoms is measured by 11-point Likert scale ranges from 0 (no symptom) to 10 (greatest severity of symptom).

    Time frame: Baseline (Week 0), and Week 16

  3. Change From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period

    Time frame: Baseline (Week 0), and Week 16

  4. Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16.

    Pigmentation will be assessed in melanin density which are numeric scores measured by spectrophotometer on 6 skin segments (forehead, left cheek, right inside upper arm, left medial forearm, right-hand side of abdomen, and left-hand side of buttock).

    Time frame: Baseline (Week 0), Week 8, and Week 16

  5. Percent Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16.

    Time frame: Baseline (Week 0), Week 8, and Week 16

  6. Total Number of Pain Events During 16-Week Double-Blind Treatment Period

    Time frame: Week 16

Other outcomes

  1. Total Number of Sunlight Exposure Episodes

    Time frame: Baseline (Week 0) and Week 16

  2. Change in Pigmentation as Measured by Melanin Density

    Time frame: Baseline (Week 0) and Week 16

  3. The Quality of Life as Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) 57

    Time frame: Baseline (Week 0) and Week 16

07

Results

Posted Jan 20, 2023

Participant flow

Participant flow — Overall Study
MilestoneMT-7117 Low DoseMT-7117 High DosePlacebo
Started333435
Completed313031
Not completed244
Withdrew: Adverse event120
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject014
Withdrew: Cs adverse findings from post- baseline nevi evaluation010

Outcome measures

PrimaryChange From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16.

Duration in minutes, of sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset. The average Duration in minutes, of sunlight exposure before the first prodromal symptom between 1 hour post sunrise and 1 hour pre-sunset. The average duration means that average of daily durations in 14-day windows before Day 1 (or week 16 Day) applied.

Time frame:
Baseline (Week 0) and Week 16
Reported as:
Mean · Minutes
Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16.
MinutesMT-7117 Low DoseMT-7117 High DosePlacebo
Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16.74.7 ± 76.892.4 ± 10021.0 ± 63.4
PrimaryChange From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16

Change from baseline to week 16 in Average Daily Duration (Minutes) of Sunlight Exposure sums any sunlight exposure time excluding any overlapped time with prodromal symptoms, including if the patients go out multiple times on the same day after the prodromal symptom had previously ended.

Time frame:
Baseline (Week 0), and Week 16
Reported as:
Mean · Minutes
Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16
MinutesMT-7117 Low DoseMT-7117 High DosePlacebo
Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 1672.6 ± 76.286.1 ± 83.919.9 ± 63.2
PrimaryChange From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16

Change from baseline to week 16 in Average Daily Mean Duration (Minutes) of Sunlight Exposure without prodromal symptoms divided by the number of sunlight exposures periods applicable that day.

Time frame:
Baseline (Week 0), and Week 16
Reported as:
Mean · Minutes
Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16
MinutesMT-7117 Low DoseMT-7117 High DosePlacebo
Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 1670.2 ± 73.459.3 ± 85.212.8 ± 46.9
SecondaryTotal Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period
Time frame:
Week 16
Reported as:
Mean · sunlight exposure episodes
Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period
sunlight exposure episodesMT-7117 Low DoseMT-7117 High DosePlacebo
Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period8.6 ± 9.37.7 ± 6.611.1 ± 13.3
SecondaryChange From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale

The Intensity of Prodromal Symptoms is measured by 11-point Likert scale ranges from 0 (no symptom) to 10 (greatest severity of symptom).

Time frame:
Baseline (Week 0), and Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale
score on a scaleMT-7117 Low DoseMT-7117 High DosePlacebo
Baseline2.0 ± 1.12.1 ± 0.92.0 ± 1.1
Week 161.7 ± 1.12.4 ± 1.72.4 ± 1.4
SecondaryChange From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period
Time frame:
Baseline (Week 0), and Week 16
Reported as:
Mean · Minutes
Change From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period
MinutesMT-7117 Low DoseMT-7117 High DosePlacebo
Change From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period55.3 ± 321.0111.0 ± 466.183.3 ± 267.2
SecondaryChange From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16.

Pigmentation will be assessed in melanin density which are numeric scores measured by spectrophotometer on 6 skin segments (forehead, left cheek, right inside upper arm, left medial forearm, right-hand side of abdomen, and left-hand side of buttock).

Time frame:
Baseline (Week 0), Week 8, and Week 16
Reported as:
Mean · unitless
Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16.
unitlessMT-7117 Low DoseMT-7117 High DosePlacebo
Change from Baseline at Week 81.4635 ± 3.16441.6557 ± 2.20990.1390 ± 0.3376
Change from Baseline at Week 161.1413 ± 0.72851.5307 ± 0.68810.1639 ± 0.3939
SecondaryPercent Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16.
Time frame:
Baseline (Week 0), Week 8, and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16.
percent changeMT-7117 Low DoseMT-7117 High DosePlacebo
% Change from Baseline at Week 830.4135 ± 32.830242.5543 ± 38.83904.2394 ± 11.9435
% Change from Baseline at Week 1644.0135 ± 43.732556.2871 ± 41.06607.4214 ± 16.7074
SecondaryTotal Number of Pain Events During 16-Week Double-Blind Treatment Period
Time frame:
Week 16
Reported as:
Mean · pain events
Total Number of Pain Events During 16-Week Double-Blind Treatment Period
pain eventsMT-7117 Low DoseMT-7117 High DosePlacebo
Total Number of Pain Events During 16-Week Double-Blind Treatment Period4.0 ± 6.43.3 ± 2.85.4 ± 4.9
Other pre-specifiedTotal Number of Sunlight Exposure Episodes
Time frame:
Baseline (Week 0) and Week 16

Results for this outcome have not been posted.

Other pre-specifiedChange in Pigmentation as Measured by Melanin Density
Time frame:
Baseline (Week 0) and Week 16

Results for this outcome have not been posted.

Other pre-specifiedThe Quality of Life as Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) 57
Time frame:
Baseline (Week 0) and Week 16

Results for this outcome have not been posted.

Adverse events

Collected over All AEs and SAEs that occurred from the time written informed consent was obtained until the end of the follow-up period (6 weeks after the last treatment visit, for safety monitoring). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-7117 Low Dose0/33 (0%)1/33 (3%)31/33 (93.9%)
MT-7117 High Dose0/35 (0%)0/35 (0%)34/35 (97.1%)
Placebo0/34 (0%)0/34 (0%)31/34 (91.2%)
Most frequent serious events
Most frequent serious events
EventMT-7117 Low DoseMT-7117 High DosePlacebo
Anaphylactic reactionImmune system disorders1/330/350/34
Most frequent other events
Showing 10 of 91
Most frequent other events
EventMT-7117 Low DoseMT-7117 High DosePlacebo
NauseaGastrointestinal disorders5/3316/354/34
EphelidesSkin and subcutaneous tissue disorders5/3311/350/34
Skin hyperpigmentationSkin and subcutaneous tissue disorders3/3311/350/34
NasopharyngitisInfections and infestations10/334/357/34
HeadacheNervous system disorders6/3310/356/34
DiarrhoeaGastrointestinal disorders4/338/354/34
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/337/353/34
FatigueGeneral disorders1/336/351/34
Photosensitivity reactionSkin and subcutaneous tissue disorders5/335/353/34
Abdominal pain upperGastrointestinal disorders3/331/355/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)MT-7117 Low DoseMT-7117 High DosePlaceboTotal
Mean41.8 ± 12.841.9 ± 1438.1 ± 12.640.6 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)MT-7117 Low DoseMT-7117 High DosePlaceboTotal
Female15251353
Male1892249
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MT-7117 Low DoseMT-7117 High DosePlaceboTotal
Hispanic or Latino1214
Not Hispanic or Latino32323498
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MT-7117 Low DoseMT-7117 High DosePlaceboTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White33333298
More than one race0000
Unknown or Not Reported0123
08

Study locations

9 sites
  • ACTCA, A Member of the Alliance, Inc.
    Los Angeles, California 90036, United States
  • University of California at San Francisco
    San Francisco, California 94143, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Metro Boston Clinical Partners, LLC
    Brighton, Massachusetts 02135, United States
  • Ichan School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Remington-Davis, Inc
    Columbus, Ohio 43215, United States
  • University of Texas Medical Branch Porphyria Center
    Galveston, Texas 77555, United States
  • University of Utah
    Salt Lake City, Utah 84108, United States
09

References and documents

Publications

  • Balwani M, Bonkovsky HL, Levy C, Anderson KE, Bissell DM, Parker C, Takahashi F, Desnick RJ, Belongie K; Endeavor Investigators. Dersimelagon in Erythropoietic Protoporphyrias. N Engl J Med. 2023 Apr 13;388(15):1376-1385. doi: 10.1056/NEJMoa2208754. PubMed 37043653 ↗
  • Ogasawara A, Ide R, Inoue S, Tsuda M, Teng R. Assessment of Potential Drug-Drug Interactions for Novel Oral Melanocortin-1 Receptor Agonist Dersimelagon. Pharmacol Res Perspect. 2025 Feb;13(1):e70069. doi: 10.1002/prp2.70069. PubMed 39887900 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Sep 2019, 14 months.

Results were first posted in Jan 2023, 3 years 3 months after primary completion. A results delay was requested in Sep 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2018
First posted
May 9, 2018
StartActual
Jul 5, 2018
Primary completionActual
Sep 28, 2019
CompletionActual
Sep 28, 2019
Results delay requested
Sep 24, 2020
Results first posted
Jan 20, 2023
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03520036
Responsible party
Sponsor
First posted
May 9, 2018
Start date
Jul 5, 2018
Primary completion
Sep 28, 2019
Completion
Sep 28, 2019
Results posted
Jan 20, 2023
Last update
Dec 31, 2025

Study contacts

Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion